Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 11 of 186 for:    BUPRENORPHINE AND NALOXONE

Adolescent Community Reinforcement Approach in Combination With Buprenorphine/Naloxone for Severe Opioid Use (A-CRA/MAT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03287180
Recruitment Status : Recruiting
First Posted : September 19, 2017
Last Update Posted : February 4, 2019
Sponsor:
Collaborators:
National Institute on Drug Abuse (NIDA)
Chestnut Health Systems
Information provided by (Responsible Party):
Justine Welsh, Emory University

Brief Summary:
The study assesses whether adding a behavioral intervention, known as the Adolescent Community Reinforcement Approach (A-CRA), to the treatment of individuals already receiving buprenorphine/naloxone can improve treatment success and retention rates in young adults with severe opioid use disorder.

Condition or disease Intervention/treatment Phase
Opioid-Related Disorders Behavior, Addictive Behavioral: Adolescent Community Reinforcement Approach (A-CRA) Other: Combination of buprenorphine/naloxone 4/1 Not Applicable

Detailed Description:
Buprenorphine is one of the medication assisted treatments approved by the FDA for opioid use disorders. Treatment with buprenorphine/naloxone may reduce the risk of opioid overdose and lower the occurrence of further conditions associated with injection drug use such as psychiatric disorders, hepatitis C infection, HIV, and high-risk sexual and criminal behaviors. The study assesses whether adding a behavioral intervention, known as the Adolescent Community Reinforcement Approach (A-CRA), to the treatment of individuals already receiving buprenorphine/naloxone can improve treatment success and retention rates in young adults with severe opioid use disorder.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: This 12-week randomized controlled pilot trial will begin by an induction on sublingual buprenorphine/naloxone for all participants who would usually receive buprenorphine based treatment in the clinic. After the two-week induction phase, participants will be randomized into two groups. While continuing buprenorphine/naloxone the experimental group will receive a 12-week course of A-CRA, while the control group will be provided medical management by the prescriber. Medical management is the standard treatment approach for prescribing buprenorphine and covers medication adherence, side effects of the medication, assessment of withdrawal/cravings and dose adjustment as indicated. After completion of the 12-week A-CRA intervention, all individuals will receive weekly medical management sessions until week 24 (6 month follow up).
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Adolescent Community Reinforcement Approach (A-CRA) Implementation in Combination With Buprenorphine/Naloxone for Young Adults Ages 18 to 25 With Severe Opioid Use Disorder
Actual Study Start Date : January 1, 2019
Estimated Primary Completion Date : August 30, 2020
Estimated Study Completion Date : August 30, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Experimental group
Participants in the experimental group will attend one individual assessment with the study physician for combination of buprenorphine/naloxone 4/1 prescription and urinalysis, along with one weekly Adolescent Community Reinforcement Approach (A-CRA) session (approximately 50 minutes).
Behavioral: Adolescent Community Reinforcement Approach (A-CRA)
The A-CRA is a modified version of the Community Reinforcement Approach for adolescents and transitional age youth. The A-CRA treatment protocol consists of nineteen procedures designed to promote positive behavior change directed towards prosocial activities and engagement in the individual's community. A community can include but is not limited to: social and peer activities, family interaction, and work or school environments. Some of the highlighted procedures include relapse prevention, sobriety sampling, problem solving, and communication skills. There are also combined parent/and or couples relationship sessions with the young adult. In the current study, 12-weeks of A-CRA treatment will be provided to the intervention group.

Other: Combination of buprenorphine/naloxone 4/1
Buprenorphine is a partial agonist at mu-opioid receptor, an antagonist at kappa-opioid receptor. Naloxone is an antagonist at the mu-opioid receptor. Buprenorphine/naloxone requires the use of an induction to avoid the risk of withdrawal. Participants are instructed not to use opioids for at least 10 hours prior to first dose. Once symptoms of withdrawal score a minimum of 7 on the Clinical Opiate Withdrawal Scale (COWS), the first dose of 4/1 mg will be given. Participants will be monitored for an hour. An additional 4/1 mg dose can be provided to a dose that suppresses withdrawal effects. The physician then provides a prescription for 8/2-16/4 mg for Day 2. Doses can be adjusted with a maximum of total 24/6 mg/day. The target daily dose is 16/4 mg.
Other Name: Suboxone/Narcan

Active Comparator: Control group
Participants in the control condition will attend weekly individual medical management sessions with the MD who will also provide a prescription for a combination of buprenorphine/naloxone 4/1 (approximately 25 minutes in duration).
Other: Combination of buprenorphine/naloxone 4/1
Buprenorphine is a partial agonist at mu-opioid receptor, an antagonist at kappa-opioid receptor. Naloxone is an antagonist at the mu-opioid receptor. Buprenorphine/naloxone requires the use of an induction to avoid the risk of withdrawal. Participants are instructed not to use opioids for at least 10 hours prior to first dose. Once symptoms of withdrawal score a minimum of 7 on the Clinical Opiate Withdrawal Scale (COWS), the first dose of 4/1 mg will be given. Participants will be monitored for an hour. An additional 4/1 mg dose can be provided to a dose that suppresses withdrawal effects. The physician then provides a prescription for 8/2-16/4 mg for Day 2. Doses can be adjusted with a maximum of total 24/6 mg/day. The target daily dose is 16/4 mg.
Other Name: Suboxone/Narcan




Primary Outcome Measures :
  1. Proportion of opiates-negative urine drug screens over the total number of urine drug screens at each stage [ Time Frame: Each session (weekly) up to 24 weeks. ]
    Qualitative urine test for opiates (+/-) will be performed. All presumptive positive assays will be confirmed by Gas Chromatography-Mass Spectrometry. The concentration value must be greater than or equal to the cutoff to be reported as positive. The opiates test results (positive/negative) will be documented. Proportion of opiates-negative urine drug screens over the total number of urine drug screens at each stage will be reported.

  2. Percent of days of opioid use within the past 90 days as indicated by self-report on the Global Appraisal of Individual Needs [ Time Frame: Pre-treatment (baseline) and post-study intervention (12 weeks visit after completion of A-CRA ), and end of follow-up (24-week visit) . ]
    The Global Appraisal of Individual Needs is a comprehensive, semi-structured interview measure with established validity and reliability used to identify and address a wide range of psychosocial problems in clinical populations. Average administration time for the GAIN Intake version is 1.5 hours and 45 minutes for the follow-up version. The assessment categories include background, school problems, work problems, physical health, sources of stress, risk behaviors and infectious diseases, mental health, substance use, and crime and violence. Substance use categories document self-reported frequency of substance use within the past 90 days for each substance endorsed (alcohol, opioids, marijuana, and other illicit psychoactive drugs). Individuals are able to say that they do not know, or refuse to answer any questions that they do not want to answer.


Secondary Outcome Measures :
  1. Completion of the final phase of treatment defined as final study session (yes/no) [ Time Frame: 24-week visit ]
    To investigate any difference in treatment retention in the experimental group compared to the control group.

  2. Number of clinic visits by patient and any expected joint family member sessions [ Time Frame: 2-, 12, and 24-week visits. ]
    To investigate any difference in treatment retention in the experimental group compared to the control group.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 25 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • have met DSM-5 criteria for severe opioid use disorder
  • no sensitivity to buprenorphine or naloxone
  • no further medical/addictive conditions that require immediate medical attention
  • ability to read and provide informed consent
  • intent to remain in the area for the duration of the study
  • able to receive outpatient care
  • agreed to use an acceptable birth control method throughout the duration of this study (female participants)

Exclusion Criteria:

  • endorsement of imminent and serious suicidality
  • medical conditions that take precedence over the presence of treatment for an addictive disorder
  • history of an adverse reaction to buprenorphine/naloxone
  • current substance use or psychiatric condition requiring a level of care higher than outpatient
  • pregnant, nursing or planning pregnancy during the extent of the treatment trial(female participants)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03287180


Contacts
Layout table for location contacts
Contact: Justine Welsh, MD 404-727-5756 justine.welsh@emory.edu
Contact: Yujia Shentu, MS 404-727-7090 yshentu@emory.edu

Locations
Layout table for location information
United States, Georgia
Executive Park Recruiting
Atlanta, Georgia, United States, 30329
Contact: Justine Welsh       justine.welsh@emory.edu   
Sponsors and Collaborators
Emory University
National Institute on Drug Abuse (NIDA)
Chestnut Health Systems
Investigators
Layout table for investigator information
Principal Investigator: Justine Welsh, MD SOM: Psych: Child Psych - CAMP Emory University

Publications:
Layout table for additonal information
Responsible Party: Justine Welsh, Assistant Professor, Emory University
ClinicalTrials.gov Identifier: NCT03287180     History of Changes
Other Study ID Numbers: IRB00093907
1R21DA046738-01 ( U.S. NIH Grant/Contract )
First Posted: September 19, 2017    Key Record Dates
Last Update Posted: February 4, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Justine Welsh, Emory University:
Adolescent Community Reinforcement Approach
A-CRA
Opioid-Related Disorders
Behavior
Psychosocial treatment
Pharmacotherapy
Randomized controlled
Adolescent
Young adult
Additional relevant MeSH terms:
Layout table for MeSH terms
Buprenorphine
Buprenorphine, Naloxone Drug Combination
Naloxone
Opioid-Related Disorders
Behavior, Addictive
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Compulsive Behavior
Impulsive Behavior
Analgesics, Opioid
Narcotics
Central Nervous System Depressants
Physiological Effects of Drugs
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Narcotic Antagonists